Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
CAT study to examine combination hormonal therapy for advanced breast cancer
March 31st, 2005
Intarcia Therapeutics, Inc., initiated its CAT (Combined Anti-estrogen Therapy) study, a global, randomized phase III study of combination hormonal therapy for the first line treatment of advanced breast cancer. Intarcia's objective is to test the hypothesis that its combination of atamestane plus toremifene (Fareston) will be more active than single agent therapy with letrozole (Femara) alone. Alice Leung, chief executive officer of Intarcia Therapeutics explained, "By complementary mechanisms of action, the combination of estrogen receptor blockade and aromatase inhibition addresses both key mechanisms by which estrogen drives breast cancer cell...
Source: Women's Health Weekly (2005-03-31)
|
